Bortezomib in Anti-Cancer Activity: A Potential Drug

Journal Title: Global Journal of Cancer Therapy - Year 2016, Vol 2, Issue 1

Abstract

26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a target therapy for cancer to promote cell cycle arrest or apoptosis. Bortezomib (Velcade®, PS-341, and Millennium Pharmaceuticals, Inc.) is the first, selective, reversible, and only proteasome inhibitor for the treatment of multiple myeloma have been approved by U.S. Food and Drug Administration (FDA) in 2003. Bortezomib downregulates the interaction of multiple myeloma cells with bone marrow stromal cells, inhibits angiogenesis, and blocks cell cycle progression. Clinically, continuous dosage of bortezomib leads to few side effects.

Authors and Affiliations

Appavu Rajagopal, Mohan Deepa

Keywords

Related Articles

Angiosarcoma of the Scalp and Face: A Hard to Treat Tumor

Cutaneous angiosarcoma is a rare and aggressive malignant tumor of vascular origin. Multimodality treatment including surgery, radiotherapy and chemotherapy should be used according to age and local spread. Prognosis is...

Primary Leiomyosarcoma of the Mandibular Gingiva

Primary oral leiomyosarcomas are exceptionally rare lesions often associated with poor prognosis. We report a case of leiomyosarcoma arising in the anterior mandibular gingiva, which is a non-prevalent site of occurrence...

The Role of Decavanadate in Anti-Tumour Activity

Decavanadate compounds were described to be involved in a variety of biological activities and responses such as anti-virus, anti-bacterial and anticancer. While the mechanisms of action of the anti-viral and anti-bacter...

Abrikossoff’s Tumour Mimicking a Neoplastic Tumour of the Breast: A Case Report

Introduction: Granular cell tumours (GCT), also known as Abrikossoff’s tumours, are rare, and occur in the breast in approximately 5-6% of the cases these tumours are usually benign with only 1% of malignancy. Case Pres...

Diagnosing HPV-Related Oropharyngeal Cancers: The Need to Speak a Common Language

Oral cavity squamous cell cancer (OSCC) and Oropharynx squamous cell carcinoma (OPSCC) are the most frequent forms of Head and Neck Cancers (HNCs) [1]. About 300,000 new cases of oral cancers are being counted yearly wor...

Download PDF file
  • EP ID EP352840
  • DOI 10.17352/2581-5407.000007
  • Views 119
  • Downloads 0

How To Cite

Appavu Rajagopal, Mohan Deepa (2016). Bortezomib in Anti-Cancer Activity: A Potential Drug. Global Journal of Cancer Therapy, 2(1), 5-8. https://europub.co.uk./articles/-A-352840